Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 3.04
CLSN's Cash-to-Debt is ranked lower than
73% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CLSN: 3.04 )
Ranked among companies with meaningful Cash-to-Debt only.
CLSN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.45  Med: 21.98 Max: No Debt
Current: 3.04
Equity-to-Asset 0.20
CLSN's Equity-to-Asset is ranked lower than
87% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CLSN: 0.20 )
Ranked among companies with meaningful Equity-to-Asset only.
CLSN' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.05  Med: 0.54 Max: 0.97
Current: 0.2
-1.05
0.97
Piotroski F-Score: 3
Altman Z-Score: -13.26
Beneish M-Score: -3.07
WACC vs ROIC
11.58%
-380.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -4058.00
CLSN's Operating Margin % is ranked lower than
88% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. CLSN: -4058.00 )
Ranked among companies with meaningful Operating Margin % only.
CLSN' s Operating Margin % Range Over the Past 10 Years
Min: -4943  Med: -3606.1 Max: -461.96
Current: -4058
-4943
-461.96
Net Margin % -4299.60
CLSN's Net Margin % is ranked lower than
89% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. CLSN: -4299.60 )
Ranked among companies with meaningful Net Margin % only.
CLSN' s Net Margin % Range Over the Past 10 Years
Min: -5098.8  Med: -3030.5 Max: -471.44
Current: -4299.6
-5098.8
-471.44
ROE % -194.64
CLSN's ROE % is ranked lower than
87% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CLSN: -194.64 )
Ranked among companies with meaningful ROE % only.
CLSN' s ROE % Range Over the Past 10 Years
Min: -689.3  Med: -93.27 Max: 257.55
Current: -194.64
-689.3
257.55
ROA % -57.80
CLSN's ROA % is ranked lower than
69% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CLSN: -57.80 )
Ranked among companies with meaningful ROA % only.
CLSN' s ROA % Range Over the Past 10 Years
Min: -217.17  Med: -50.3 Max: 121.96
Current: -57.8
-217.17
121.96
ROC (Joel Greenblatt) % -3753.04
CLSN's ROC (Joel Greenblatt) % is ranked lower than
76% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CLSN: -3753.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CLSN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4101.97  Med: -2248.77 Max: -115.63
Current: -3753.04
-4101.97
-115.63
3-Year Revenue Growth Rate -19.90
CLSN's 3-Year Revenue Growth Rate is ranked lower than
75% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. CLSN: -19.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CLSN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: -19.9
Current: -19.9
3-Year EBITDA Growth Rate 14.90
CLSN's 3-Year EBITDA Growth Rate is ranked higher than
67% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CLSN: 14.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CLSN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -57.6  Med: -4.7 Max: 39.1
Current: 14.9
-57.6
39.1
3-Year EPS without NRI Growth Rate -3.60
CLSN's 3-Year EPS without NRI Growth Rate is ranked lower than
51% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CLSN: -3.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CLSN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.2  Med: -4.75 Max: 33.9
Current: -3.6
-48.2
33.9
GuruFocus has detected 3 Warning Signs with Celsion Corp $CLSN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CLSN's 30-Y Financials

Financials (Next Earnings Date: 2017-08-12 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

CLSN Guru Trades in Q2 2016

Jim Simons 51,848 sh (+87.53%)
» More
Q3 2016

CLSN Guru Trades in Q3 2016

Jim Simons 137,985 sh (+166.13%)
» More
Q4 2016

CLSN Guru Trades in Q4 2016

Jim Simons 684,798 sh (+396.28%)
» More
Q1 2017

CLSN Guru Trades in Q1 2017

Jim Simons 1,375,147 sh (+100.81%)
» More
» Details

Insider Trades

Latest Guru Trades with CLSN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:MATN, NAS:SNGX, NAS:TENX, AMEX:HEB, OTCPK:CRYO, OTCPK:CDXI, NAS:MBRX, NAS:KTOV, OTCPK:OPNT, NAS:RPRX, NAS:XTLB, NAS:PZRX, OTCPK:BLUSF, OTCPK:RGIN, OTCPK:BCTXF, NAS:SBOT, OTCPK:ENUM, OTCBB:DDRT, OTCPK:ENDV, NAS:RXII » details
Traded in other countries:CBOB.Germany,
Headquarter Location:USA
Celsion Corp is a fully-integrated oncology drug development company. The Company is engaged in developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies.

Celsion Corp was founded in 1982 and is a Delaware corporation. The Company is a fully-integrated oncology drug development company. The Company is engaged in developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's product include ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). The Company's pipeline also includes GEN-1 a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence. It is also working to develop and commercialize oncology therapies based on its technologies by developing novel therapeutics for cancer treatment. The Company faces competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The Company is subject to the periodic inspection of its clinical trials, facilities, procedures and operations and/or the testing of its products by the FDA to determine whether its systems and processes are in compliance with FDA regulations. The Company's research and development activities, pre-clinical tests and clinical trials, and ultimately the manufacturing, marketing and labeling of its products, are all subject to regulation by the FDA and foreign regulatory agencies.

Top Ranked Articles about Celsion Corp

Celsion Corporation to Hold First Quarter 2017 Financial Results Conference Call on Friday, May 12, 2017
Celsion Updates Clinical Data from the OVATION Study in Newly Diagnosed  Advanced Ovarian Cancer Patients
Celsion Announces Presentation of OVATION Study Findings at the Upcoming ASCO 2017 Annual Meeting
Celsion Corporation Reports Preclinical Results of ThermoDox® for the Treatment of Bladder Cancer Published in the International Journal of Hyperthermia
Celsion Corporation to Hold Year-End 2016 Financial Results Conference Call on Thursday, March 16, 2017

LAWRENCEVILLE, N.J., March 09, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss year-end 2016 financial results and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. ET on Thursday, March 16, 2017. To participate in the call, interested parties may dial 1-888-490-2763 (Toll-Free/North America) or 1-719-325-2481 (International/Toll) and ask for the Celsion Corporation 4th Quarter 2016 Earnings Call (Conference Code: 8052561) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at www.celsion.com.
The call will be archived for replay on Thursday, March 16, 2017 and will remain available until Thursday, March 30, 2017. The replay can be accessed at 1-888-203-1112 (Toll-Free/North America) or 1-719-457-0820 (International/Toll) using Conference Code: 8052561. An audio replay of the call will also be available on the Company’s website, www.celsion.com, for 30 days after 2:00 p.m. ET on Thursday, March 16, 2017. About Celsion Corporation Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer.  The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers.  Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence.  For more information on Celsion, visit our website: www.celsion.com.
Celsion Investor Contact

Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.67
CLSN's PB Ratio is ranked higher than
89% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CLSN: 1.67 )
Ranked among companies with meaningful PB Ratio only.
CLSN' s PB Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2 Max: 167.59
Current: 1.67
0.81
167.59
PS Ratio 15.00
CLSN's PS Ratio is ranked lower than
56% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CLSN: 15.00 )
Ranked among companies with meaningful PS Ratio only.
CLSN' s PS Ratio Range Over the Past 10 Years
Min: 2.22  Med: 21.67 Max: 585.38
Current: 15
2.22
585.38
EV-to-EBIT -0.50
CLSN's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CLSN: -0.50 )
Ranked among companies with meaningful EV-to-EBIT only.
CLSN' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.6  Med: -3.15 Max: 0.3
Current: -0.5
-12.6
0.3
EV-to-EBITDA -0.53
CLSN's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CLSN: -0.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
CLSN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.4  Med: -3.25 Max: 0.3
Current: -0.53
-13.4
0.3
Current Ratio 0.52
CLSN's Current Ratio is ranked lower than
93% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CLSN: 0.52 )
Ranked among companies with meaningful Current Ratio only.
CLSN' s Current Ratio Range Over the Past 10 Years
Min: 0.3  Med: 4.3 Max: 104.65
Current: 0.52
0.3
104.65
Quick Ratio 0.52
CLSN's Quick Ratio is ranked lower than
92% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CLSN: 0.52 )
Ranked among companies with meaningful Quick Ratio only.
CLSN' s Quick Ratio Range Over the Past 10 Years
Min: 0.3  Med: 3.72 Max: 104.65
Current: 0.52
0.3
104.65
Days Sales Outstanding 2.92
CLSN's Days Sales Outstanding is ranked higher than
95% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CLSN: 2.92 )
Ranked among companies with meaningful Days Sales Outstanding only.
CLSN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.92  Med: 98.92 Max: 2190
Current: 2.92
2.92
2190

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -24.20
CLSN's 3-Year Average Share Buyback Ratio is ranked lower than
74% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CLSN: -24.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CLSN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -66.2  Med: -28.1 Max: 1.9
Current: -24.2
-66.2
1.9

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.69
CLSN's Price-to-Median-PS-Value is ranked higher than
72% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CLSN: 0.69 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CLSN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 3.84 Max: 3843.67
Current: 0.69
0
3843.67
Earnings Yield (Greenblatt) % -198.78
CLSN's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CLSN: -198.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CLSN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -217.3  Med: 715.7 Max: 887.9
Current: -198.78
-217.3
887.9

More Statistics

Revenue (TTM) (Mil) $0.50
EPS (TTM) $ -0.73
Beta1.32
Short Percentage of Float10.87%
52-Week Range $0.19 - 1.60
Shares Outstanding (Mil)56.98

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1 1 1
EPS ($) -0.38 -0.22 -0.24
EPS without NRI ($) -0.38 -0.22 -0.24
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CLSN

Headlines

Articles On GuruFocus.com
Celsion Corporation to Hold First Quarter 2017 Financial Results Conference Call on Friday, May 12, May 05 2017 
Celsion Updates Clinical Data from the OVATION Study in Newly Diagnosed  Advanced Ovarian Canc May 04 2017 
Celsion Announces Presentation of OVATION Study Findings at the Upcoming ASCO 2017 Annual Meeting Apr 20 2017 
Celsion Corporation Reports Preclinical Results of ThermoDox® for the Treatment of Bladder Cancer Apr 13 2017 
Celsion Corporation to Hold Year-End 2016 Financial Results Conference Call on Thursday, March 16, 2 Mar 09 2017 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 6,000 Shares Nov 19 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 5,000 Shares Aug 17 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 3,750 Shares Mar 18 2009 

More From Other Websites
Edited Transcript of CLSN earnings conference call or presentation 12-May-17 3:00pm GMT May 20 2017
Investor Network: Celsion Corporation to Host Earnings Call May 12 2017
Celsion Corporation Reports First Quarter 2017 Financial Results and Provides Business Update May 12 2017
Celsion Corporation to Hold First Quarter 2017 Financial Results Conference Call on Friday, May 12,... May 05 2017
Celsion Updates Clinical Data from the OVATION Study in Newly Diagnosed  Advanced Ovarian Cancer... May 04 2017
ETFs with exposure to Celsion Corp. : April 27, 2017 Apr 27 2017
Celsion Announces Presentation of OVATION Study Findings at the Upcoming ASCO 2017 Annual Meeting Apr 20 2017
Celsion Corporation Reports Preclinical Results of ThermoDox® for the Treatment of Bladder Cancer... Apr 13 2017
Celsion Corp. :CLSN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017 Mar 29 2017
Celsion Corporation Reports Year End 2016 Financial Results and Provides Business Update Mar 16 2017
Forget Gilead, Buy These Small-Cap Biotech Stocks Instead Mar 15 2017
Celsion Corporation to Hold Year-End 2016 Financial Results Conference Call on Thursday, March 16,... Mar 09 2017
Celsion Presents Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC... Feb 27 2017
Celsion Corp. Cancer Medications Insider Buying and Analysis Feb 21 2017
ETFs with exposure to Celsion Corp. : January 19, 2017 Jan 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat